3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
16
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Hypertension, Portal
1
Hepato Cellular Carcinoma
1
Hematologic Neoplasms
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
pembrolizumab
57
Nivolumab
50
Ipilimumab
31
Specimen Handling
23
Magnetic Resonance Spectroscopy
19
Cyclophosphamide
14
Biopsy
11
fludarabine
10
binimetinib
10
Opdualag
10
trametinib
9
relatlimab
9
Radiosurgery
9
CTLA-4 Antigen
9
dabrafenib
8
lifileucel
7
fludarabine phosphate
7
aldesleukin
7
encorafenib
6
Interleukin-2
6
cemiplimab
5
atezolizumab
5
Paclitaxel
5
Blood Specimen Collection
5
X-Rays
4
Taxes
4
Pemetrexed
4
Gemcitabine
4
Cisplatin
4
Carboplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Melanoma
×
tremelimumab
×
90 days
×
Clear all
No trials found.